# An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders

> **NCT01064973** · PHASE2 · TERMINATED · sponsor: **Seaside Therapeutics, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Autism Spectrum Disorders

## Interventions

- **DRUG:** arbaclofen

## Key facts

- **NCT ID:** NCT01064973
- **Lead sponsor:** Seaside Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** all active subjects were rolled into study 209AS209/NCT01706523
- **Last updated:** 2012-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064973, "An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01064973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*